Amos Baruch - Senior Scientist, OMNI Biomarker Development

Amos Baruch

Senior Scientist, OMNI Biomarker Development

"Being a Scientist at Genentech provides the ultimate combination of advancing medicine to help patients and pursuing cutting-edge biomedical research."
Years at Genentech

I relocated to the US to pursue postdoctoral studies at the Scripps Research Institute with Dr. Bernard Gilula and thereafter in the department of Biochemistry and Biophysics at UCSF with Dr. Matthew Bogyo. Thereafter, I joined Celera Genomics and led the Chemical Proteomics group charged with providing biomarker support for small molecule programs in the areas of Cancer, Asthma and Autoimmune diseases.

I then joined KAI Pharmaceuticals and championed the preclinical research and development of therapeutic peptides for hyperparathyroidism in renal dialysis patients. The lead candidate from this effort was just recently launched.

I joined Genentech at the turn of 2011 as a Scientist in the OMNI Biomarker Development group.

Featured Publication

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.

EBioMedicine. 2015 May 30;2(7):730-43.

Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, Ross J, Wyatt SK, Gandham VD, Carano RA, Dunshee DR, Wu AL, Haley B, Anderson K, Warming S, Rairdan XY, Lewin-Koh N, Zhang Y, Gutierrez J, Baruch A, Gelzleichter TR, Stevens D, Rajan S, Bainbridge TW, Vernes JM, Meng YG, Ziai J, Soriano RH, Brauer MJ, Chen Y, Stawicki S, Kim HS, Comps-Agrar L, Luis E, Spiess C, Wu Y, Ernst JA, McGuinness OP, Peterson AS, Sonoda J.

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.

AAPS J. 2015 Jul;17(4):881-90.

Budha NR, Leabman M, Jin JY, Wada DR, Baruch A, Peng K, Tingley WG, Davis JD.